Analysis of laboratory and clinical outcomes in combined data from the University of Ibadan, UIC, and Walk-PHaSST cohorts
| . | N . | High risk . | N . | Standard risk . | P* . |
|---|---|---|---|---|---|
| WBC count, × 103/µL | 329 | 10.7 (8.5-13.5) | 567 | 10.2 (8.2-12.6) | .049 |
| Hemoglobin, g/dL | 329 | 8.2 (7.2-9.3) | 567 | 8.5 (7.5-9.5) | .0055 |
| Reticulocyte, % | 259 | 11.5 (7.9-16.7) | 434 | 9.6 (6.2-13.9) | 1.0 × 10−5 |
| VOCs ≥3/y, n (%) | 329 | 181 (55) | 567 | 306 (54) | .3 |
| Stroke history, n (%) | 329 | 57 (17) | 567 | 53 (9) | .0002 |
| . | N . | High risk . | N . | Standard risk . | P* . |
|---|---|---|---|---|---|
| WBC count, × 103/µL | 329 | 10.7 (8.5-13.5) | 567 | 10.2 (8.2-12.6) | .049 |
| Hemoglobin, g/dL | 329 | 8.2 (7.2-9.3) | 567 | 8.5 (7.5-9.5) | .0055 |
| Reticulocyte, % | 259 | 11.5 (7.9-16.7) | 434 | 9.6 (6.2-13.9) | 1.0 × 10−5 |
| VOCs ≥3/y, n (%) | 329 | 181 (55) | 567 | 306 (54) | .3 |
| Stroke history, n (%) | 329 | 57 (17) | 567 | 53 (9) | .0002 |
Values are expressed as medians and IQRs.
P value adjusted for age, sex, hydroxyurea therapy, and site by using linear and logistic regression analysis.